Only a minority of lung cancer patients respond to current immunotherapy drugs, and this trial will test whether personalised DNA vaccines can change that. The problem is that checkpoint inhibitors—the standard immunotherapy—only work when a patient’s tumour already contains enough cancer-fighting immune cells. This happens in roughly 20–30% of cancers, leaving most patients without benefit. The logical next step is to train the immune system to produce more of those cells. Vaccines are a proven way to do that, and the mutations unique to each patient’s tumour provide ideal targets. This project combines that approach with a new type of DNA vaccine called a “doggybone DNA vaccine,” which can be manufactured rapidly enough to be practical in a clinical setting. If successful, the vaccine could activate cancer-specific immune cells in the blood, get them to travel into the tumour tissue, and improve the effectiveness of standard pembrolizumab treatment for advanced lung cancer. The researchers will also assess safety and gather early data on whether the vaccine boosts survival. A positive result would pave the way for larger studies testing this personalised vaccination strategy across different cancers and stages of disease, potentially shifting how immunotherapy is used.
View original technical description
Cancer immunotherapy has led to a landmark change in cancer treatment and can offer long term cancer free survival, and possibly a cure, even to patients with advanced cancer. However, even in cancer types, such as lung cancer, where immunotherapy can work, only a minority of patients benefit. The current best tools, such as checkpoint inhibitors, treat cancer by 'waking up and activating' cancer-reactive immune cells that are present in the cancer tissue naturally in sufficient numbers. We now know that this is the case in only about 20-30% of cancers, and this is a critical reason why we appear to have hit a ceiling in clinical benefit with existing treatments. The logical way of overcoming this limitation is by training the patient's immune system to produce more T cells that can recognise and attack cancer cells. Vaccination is a well-established tool for training the immune system to become active against new targets, and a growing body of evidence suggests vaccines can be used successfully against cancer. Very promising targets for immune attack are the mutations, that distinguish cancer cells from healthy cells. It is now possible to 'read out' these differences and then to use these mutations as templates for vaccines. Here we will to bring together this approach with our long-standing expertise in making and testing DNA vaccines in cancer patients. A new type of DNA vaccines, called 'doggybone DNA vaccines' will be used to make a new vaccine tailored for each patient. This method is remarkably rapid and will allow us to make a bespoke vaccine in a timely fashion. We will evaluate how realistic it is in clinical practice to produce a vaccine in a small number of weeks after starting the standard immunotherapy (pembrolizumab) treatment for advanced lung cancer. We will be focussing on lung cancer as this is one of the most common cancers and one where most patients with advanced disease, that cannot be removed by surgery, still die from the cancer. We will test: if the vaccine can activate the right immune cells in the blood, and whether these immune cells can travel to the cancer tissue and become enriched there after vaccination. We will collect information on how safe this approach will be, although we do not predict that we will cause side effects beyond those from the standard immunotherapy. We will collect early information on whether the vaccine improves the benefit of standard immunotherapy. If successful, we will develop a larger study to investigate if the principles we are testing here are applicable to all kinds of cancer and for patients at different steps of their cancer journey, potentially leading to a landmark change in the way we use immunotherapy.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know